{"id":"W2127680641","doi":"10.1158/1078-0432.ccr-05-2255","title":"Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Internal medicine; Mucositis; Neutropenia; Cyclophosphamide; Chemotherapy; Gastroenterology; Vinblastine; Regimen; Surgery; Clinical endpoint; Performance status; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179346,0.0003227787,0.0006608588,0.00009625321,0.0002416503,0.00005145893,0.0002699108,0.0002962989,0.0000254823],"category_scores_gemma":[0.0003740058,0.0002243716,0.0001547184,0.0003515795,0.0007261411,0.00001976604,0.0002496109,0.0004323683,0.000004315723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001247457,"about_ca_system_score_gemma":0.0008152924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006639612,"about_ca_topic_score_gemma":0.002869199,"domain_scores_codex":[0.9957941,0.0004900413,0.001238499,0.001195683,0.0005286011,0.000753037],"domain_scores_gemma":[0.9981542,0.0002562315,0.0002728077,0.0005859127,0.0004249339,0.0003059624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4476258,0.009993664,0.4381023,0.00004196322,0.0001750837,0.00007058058,0.00003835566,0.0002099898,0.001146635,0.00001573167,0.003708136,0.09887177],"study_design_scores_gemma":[0.453378,0.1268916,0.3924806,0.0003782584,0.00007170874,0.00000207526,0.00008685932,0.0001725103,0.003493457,0.00003858245,0.02222087,0.0007855932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960515,0.001812273,0.00001320181,0.0002510456,0.0002295845,0.001255711,0.0001213954,0.00001461537,0.0002506],"genre_scores_gemma":[0.9948273,0.002068579,0.0004310929,0.0001296036,0.0009161283,0.0003203467,0.0002204396,0.00005952031,0.001027012],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1168979,"threshold_uncertainty_score":0.9149609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07054438524096894,"score_gpt":0.4518263761429414,"score_spread":0.3812819909019725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}